{"id":19215,"date":"2025-01-13T17:55:13","date_gmt":"2025-01-13T20:55:13","guid":{"rendered":"https:\/\/ptbr.idor.org\/pesquisa\/ensaiosclinicos\/prism-mel-301-melanoma-avancado-1a-linha\/"},"modified":"2025-01-13T17:55:13","modified_gmt":"2025-01-13T20:55:13","slug":"prism-mel-301-melanoma-avancado-1a-linha","status":"publish","type":"ensaio_clinico","link":"https:\/\/www.rededorsaoluiz.com.br\/instituto\/idor\/pesquisa\/ensaiosclinicos\/prism-mel-301-melanoma-avancado-1a-linha\/","title":{"rendered":"PRISM-MEL-301 &#8211; Melanoma avan\u00e7ado \u2013 1\u00aa linha"},"content":{"rendered":"<div data-olk-copy-source=\"MessageBody\">Regimes de IMC-F106C versus regimes de Nivolumabe em participantes com melanoma avan\u00e7ado n\u00e3o tratado anteriormente.<\/div>\n<div><b>&nbsp;<\/b><\/div>\n<div><b>Popula\u00e7\u00e3o:&nbsp;<\/b>\u2265 18 anos de idade. Melanoma est\u00e1gio IV ou est\u00e1gio III irressec\u00e1vel confirmado histologicamente. Status da muta\u00e7\u00e3o BRAF V600 determinado. Positivos para HLA-A*02:01 (exame realizado pelo laborat\u00f3rio central). Doen\u00e7a mensur\u00e1vel, conforme RECIST 1.1. ECOG 0 ou 1. Met\u00e1stase em SNC ou meningite carcinomatosa n\u00e3o tratada, ativa ou sintom\u00e1tica. Terapia antic\u00e2ncer sist\u00eamica anterior para melanoma irressec\u00e1vel ou metast\u00e1tico (obs: terapias adjuvantes ou neoadjuvantes anteriores s\u00e3o permitidas).<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Regimes de IMC-F106C versus regimes de Nivolumabe em participantes com melanoma avan\u00e7ado n\u00e3o tratado anteriormente. &nbsp; Popula\u00e7\u00e3o:&nbsp;\u2265 18 anos de idade. Melanoma est\u00e1gio IV ou est\u00e1gio III irressec\u00e1vel confirmado histologicamente. Status da muta\u00e7\u00e3o BRAF V600 determinado. Positivos para HLA-A*02:01 (exame realizado pelo laborat\u00f3rio central). Doen\u00e7a mensur\u00e1vel, conforme RECIST 1.1. ECOG 0 ou 1. Met\u00e1stase em [&hellip;]<\/p>\n","protected":false},"featured_media":0,"template":"","meta":{"_acf_changed":false},"class_list":["post-19215","ensaio_clinico","type-ensaio_clinico","status-publish","hentry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>PRISM-MEL-301 - Melanoma avan\u00e7ado \u2013 1\u00aa linha - IDOR - Instituto D&#039;Or de Pesquisa e Ensino<\/title>\n<link rel=\"canonical\" href=\"https:\/\/ptbr.idor.org\/pesquisa\/ensaiosclinicos\/prism-mel-301-melanoma-avancado-1a-linha\/\" \/>\n<meta property=\"og:locale\" content=\"pt_BR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"PRISM-MEL-301 - Melanoma avan\u00e7ado \u2013 1\u00aa linha - IDOR - Instituto D&#039;Or de Pesquisa e Ensino\" \/>\n<meta property=\"og:description\" content=\"Regimes de IMC-F106C versus regimes de Nivolumabe em participantes com melanoma avan\u00e7ado n\u00e3o tratado anteriormente. &nbsp; Popula\u00e7\u00e3o:&nbsp;\u2265 18 anos de idade. Melanoma est\u00e1gio IV ou est\u00e1gio III irressec\u00e1vel confirmado histologicamente. Status da muta\u00e7\u00e3o BRAF V600 determinado. Positivos para HLA-A*02:01 (exame realizado pelo laborat\u00f3rio central). Doen\u00e7a mensur\u00e1vel, conforme RECIST 1.1. ECOG 0 ou 1. Met\u00e1stase em [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ptbr.idor.org\/pesquisa\/ensaiosclinicos\/prism-mel-301-melanoma-avancado-1a-linha\/\" \/>\n<meta property=\"og:site_name\" content=\"IDOR - Instituto D&#039;Or de Pesquisa e Ensino\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/ptbr.idor.org\\\/pesquisa\\\/ensaiosclinicos\\\/prism-mel-301-melanoma-avancado-1a-linha\\\/\",\"url\":\"https:\\\/\\\/ptbr.idor.org\\\/pesquisa\\\/ensaiosclinicos\\\/prism-mel-301-melanoma-avancado-1a-linha\\\/\",\"name\":\"PRISM-MEL-301 - Melanoma avan\u00e7ado \u2013 1\u00aa linha - IDOR - Instituto D&#039;Or de Pesquisa e Ensino\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/ptbr.idor.org\\\/#website\"},\"datePublished\":\"2025-01-13T20:55:13+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/ptbr.idor.org\\\/pesquisa\\\/ensaiosclinicos\\\/prism-mel-301-melanoma-avancado-1a-linha\\\/#breadcrumb\"},\"inLanguage\":\"pt-BR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/ptbr.idor.org\\\/pesquisa\\\/ensaiosclinicos\\\/prism-mel-301-melanoma-avancado-1a-linha\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/ptbr.idor.org\\\/pesquisa\\\/ensaiosclinicos\\\/prism-mel-301-melanoma-avancado-1a-linha\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"In\u00edcio\",\"item\":\"https:\\\/\\\/ptbr.idor.org\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Ensaios Cl\u00ednicos\",\"item\":\"https:\\\/\\\/ptbr.idor.org\\\/pesquisa\\\/ensaiosclinicos\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"PRISM-MEL-301 &#8211; Melanoma avan\u00e7ado \u2013 1\u00aa linha\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/ptbr.idor.org\\\/#website\",\"url\":\"https:\\\/\\\/ptbr.idor.org\\\/\",\"name\":\"IDOR - Instituto D&#039;Or de Pesquisa e Ensino\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/ptbr.idor.org\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"pt-BR\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"PRISM-MEL-301 - Melanoma avan\u00e7ado \u2013 1\u00aa linha - IDOR - Instituto D&#039;Or de Pesquisa e Ensino","canonical":"https:\/\/ptbr.idor.org\/pesquisa\/ensaiosclinicos\/prism-mel-301-melanoma-avancado-1a-linha\/","og_locale":"pt_BR","og_type":"article","og_title":"PRISM-MEL-301 - Melanoma avan\u00e7ado \u2013 1\u00aa linha - IDOR - Instituto D&#039;Or de Pesquisa e Ensino","og_description":"Regimes de IMC-F106C versus regimes de Nivolumabe em participantes com melanoma avan\u00e7ado n\u00e3o tratado anteriormente. &nbsp; Popula\u00e7\u00e3o:&nbsp;\u2265 18 anos de idade. Melanoma est\u00e1gio IV ou est\u00e1gio III irressec\u00e1vel confirmado histologicamente. Status da muta\u00e7\u00e3o BRAF V600 determinado. Positivos para HLA-A*02:01 (exame realizado pelo laborat\u00f3rio central). Doen\u00e7a mensur\u00e1vel, conforme RECIST 1.1. ECOG 0 ou 1. Met\u00e1stase em [&hellip;]","og_url":"https:\/\/ptbr.idor.org\/pesquisa\/ensaiosclinicos\/prism-mel-301-melanoma-avancado-1a-linha\/","og_site_name":"IDOR - Instituto D&#039;Or de Pesquisa e Ensino","twitter_card":"summary_large_image","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/ptbr.idor.org\/pesquisa\/ensaiosclinicos\/prism-mel-301-melanoma-avancado-1a-linha\/","url":"https:\/\/ptbr.idor.org\/pesquisa\/ensaiosclinicos\/prism-mel-301-melanoma-avancado-1a-linha\/","name":"PRISM-MEL-301 - Melanoma avan\u00e7ado \u2013 1\u00aa linha - IDOR - Instituto D&#039;Or de Pesquisa e Ensino","isPartOf":{"@id":"https:\/\/ptbr.idor.org\/#website"},"datePublished":"2025-01-13T20:55:13+00:00","breadcrumb":{"@id":"https:\/\/ptbr.idor.org\/pesquisa\/ensaiosclinicos\/prism-mel-301-melanoma-avancado-1a-linha\/#breadcrumb"},"inLanguage":"pt-BR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ptbr.idor.org\/pesquisa\/ensaiosclinicos\/prism-mel-301-melanoma-avancado-1a-linha\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/ptbr.idor.org\/pesquisa\/ensaiosclinicos\/prism-mel-301-melanoma-avancado-1a-linha\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"In\u00edcio","item":"https:\/\/ptbr.idor.org\/"},{"@type":"ListItem","position":2,"name":"Ensaios Cl\u00ednicos","item":"https:\/\/ptbr.idor.org\/pesquisa\/ensaiosclinicos\/"},{"@type":"ListItem","position":3,"name":"PRISM-MEL-301 &#8211; Melanoma avan\u00e7ado \u2013 1\u00aa linha"}]},{"@type":"WebSite","@id":"https:\/\/ptbr.idor.org\/#website","url":"https:\/\/ptbr.idor.org\/","name":"IDOR - Instituto D&#039;Or de Pesquisa e Ensino","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/ptbr.idor.org\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"pt-BR"}]}},"_links":{"self":[{"href":"https:\/\/www.rededorsaoluiz.com.br\/instituto\/idor\/wp-json\/wp\/v2\/ensaio_clinico\/19215","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.rededorsaoluiz.com.br\/instituto\/idor\/wp-json\/wp\/v2\/ensaio_clinico"}],"about":[{"href":"https:\/\/www.rededorsaoluiz.com.br\/instituto\/idor\/wp-json\/wp\/v2\/types\/ensaio_clinico"}],"wp:attachment":[{"href":"https:\/\/www.rededorsaoluiz.com.br\/instituto\/idor\/wp-json\/wp\/v2\/media?parent=19215"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}